---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-23-000571"
form_type: "8-K"
ticker: null
cik: "0000910267"
company_name: "TITAN PHARMACEUTICALS INC"
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T19:11:13.150729+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Titan Pharma receives Nasdaq delisting notice for missing annual shareholder meeting

## Summary
- Nasdaq notice for failure to hold annual meeting within 12 months of Dec 31, 2021 fiscal year end.
- No immediate effect on listing; company has 45 days to submit a compliance plan.
- If plan accepted, exception may be granted until June 29, 2023 to regain compliance.
- Failure to regain compliance could lead to delisting of TTNP common stock from Nasdaq.
- Company intends to schedule annual meeting and submit plan to regain compliance.

## SEC filing metadata
- accession: 0001829126-23-000571
- form_type: 8-K
- cik: 0000910267
- company_name: TITAN PHARMACEUTICALS INC
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/910267/000182912623000571/0001829126-23-000571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/910267/000182912623000571/titanpharma_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-23-000571
- JSON: https://secwatch.observer/filing/0001829126-23-000571.json
- Plain text: https://secwatch.observer/filing/0001829126-23-000571.txt

## Key facts
- Listing & Compliance Notices
  TITAN PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: shareholders
  - Rules: 5620(a), 5810(c)(2)(G)
  source text: January 4, 2023, Titan Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Staff of The Nasdaq Capital Market (“Nasdaq”) that the Company is in noncompliance with Listing Rules 5620(a) and 5810(c)(2)(G) as a result of its failure to hold an annual shareholder meeting within twelve months of the December 31, 2021 fiscal year end. The Notice has no immediate effect on the Company’s listing on the Nasdaq Capital Market. The Company now has 45 days to submit a plan to regain compliance. If that plan is accepted by Nasdaq, then the Company m
  evidence_url: https://www.sec.gov/Archives/edgar/data/910267/000182912623000571/0001829126-23-000571-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.